EUVIMEDEUVIMED entdecken
Crossref

Efficacy and safety of finerenone with SGLT2i in IgA nephropathy

Yanhong Guo, Silu Zhao, Yanna Dong, Yulin Wang, Liuwei Wang, Qiuhong Li, Zihan Zhai, Lu Yu, Lin Tang

Nephrology Dialysis Transplantation · 29.05.2026 · 41 (6) · 1138-1146

DOI: 10.1093/ndt/gfaf244 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 07.11.2025. Verfasst von Yanhong Guo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephropathy, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. Hauptthemen laut MEDLINE: Glomerulonephritis, IGA, Sodium-Glucose Transporter 2 Inhibitors, Proteinuria, Naphthyridines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study aimed to compare the renal protective effects and safety profile of finerenone plus sodium-glucose cotransporter-2 inhibitor (SGLT2i) therapy versus monotherapy in patients with immunoglobulin A (IgA) nephropathy.

Methods

The retrospective study evaluated 76 patients with biopsy-proven IgA nephropathy at the First Affiliated Hospital of Zhengzhou University (2023–24). Participants were divided into three groups: finerenone plus SGLT2i group (n = 26), finerenone monotherapy group (n = 32) and SGLT2i monotherapy group (n = 18). Changes in urinary protein-to-creatinine ratio (UPCR) and estimated glomerular filtration rate at 3 and 6 months were evaluated. Safety assessments focused on hyperkalemia incidence and treatment-emergent adverse events.

Results

The combination therapy demonstrated superior proteinuria reduction compared with monotherapies, with median UPCR reductions of 40.89% at Month 3 and 54.62% at Month 6 versus 23.72%/30.88% (finerenone) and 24.69%/24.69% (SGLT2i) (all P < .05). Significantly more patients achieved ≥50% UPCR reduction in the finerenone plus SGLT2i group at Month 6 (53.8% vs 25.0% and 22.2%, P = .033). Logistic regression analysis demonstrated adjusted odds ratios ranging from 3.87 to 18.90 for finerenone plus SGLT2i therapy achieving ≥50% proteinuria reduction (all P < .05). Renal function parameters remained stable in all treatment groups without significant intergroup differences (all P > .05). The safety profile showed comparable hyperkalemia incidence rates between groups (P = .332). No severe adverse events or treatment withdrawals attributable to hyperkalemia were observed.

Conclusion

Our study shows that combined finerenone-SGLT2i therapy has a more rapid and superior proteinuria reduction versus monotherapy in IgA nephropathy, with preserved renal function and good safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glomerulonephritis, IGASodium-Glucose Transporter 2 InhibitorsProteinuriaNaphthyridinesHumansFemaleMaleRetrospective StudiesAdultGlomerular Filtration RateFollow-Up StudiesDrug Therapy, CombinationMiddle AgedPrognosisKidney Function TestsHyperkalemia

Stichwörter der Autor:innen

IgA nephropathySGLT2 inhibitorsfinerenonehyperkalemiaproteinuria

Substanzen

Sodium-Glucose Transporter 2 InhibitorsNaphthyridinesfinerenone

Autor:innen und Institutionen

  • Department of Nephropathy, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Guo, Y., Zhao, S., Dong, Y., Wang, Y., Wang, L., Li, Q., Zhai, Z., Yu, L., & Tang, L. (2026). Efficacy and safety of finerenone with SGLT2i in IgA nephropathy. Nephrology Dialysis Transplantation, 41(6), 1138-1146. https://doi.org/10.1093/ndt/gfaf244

Vancouver

Guo Y, Zhao S, Dong Y, Wang Y, Wang L, Li Q, et al. Efficacy and safety of finerenone with SGLT2i in IgA nephropathy. Nephrology Dialysis Transplantation. 2026;41(6):1138-1146. doi:10.1093/ndt/gfaf244

BibTeX
@article{Guo2026,
  author = {Guo, Yanhong and Zhao, Silu and Dong, Yanna and Wang, Yulin and Wang, Liuwei and Li, Qiuhong and Zhai, Zihan and Yu, Lu and Tang, Lin},
  title = {Efficacy and safety of finerenone with SGLT2i in IgA nephropathy},
  journal = {Nephrology Dialysis Transplantation},
  year = {2026},
  volume = {41},
  number = {6},
  pages = {1138--1146},
  doi = {10.1093/ndt/gfaf244}
}
Kostenlos starten →